Sat.Jul 23, 2022 - Fri.Jul 29, 2022

article thumbnail

Connect in Pharma launches art exhibition and charity partnership to raise funds for rare disease research

Drug Discovery Today

Geneva-based event pledges five Swiss francs per visitor to support new drug development project

Disease 113
article thumbnail

Atopic dermatitis research round-up

Antidote

Atopic dermatitis is a type of eczema, a skin condition caused by an overactive immune system that can lead to redness, blotchiness, and itching, typically on the face, arms, and legs. Atopic dermatitis is the most common type of eczema , impacting more than 9.6 million children and 16.5 million adults worldwide.

article thumbnail

CBD Research: A Dive into the Regulations of Cannabis Research

Advarra

Cannabis use has become widespread. As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. Currently, cannabis use is legal across many states in the U.S., with 37 states approving medicinal use and 18 approving recreationally. However, it’s not legal federally and is considered a Schedule I drug by the U.S.

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from May 2022. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Lab Innovations 2022 to drive innovation and sustainability

Drug Discovery Today

Registration is open for the UK’s largest trade show for the lab industry

113
113
article thumbnail

The importance of diversity in kidney disease trials: A Q&A with the American Kidney Fund

Antidote

Kidney diseases are one of the top causes of death in the United States , and worldwide, they impact nearly 10% of the population each year. Because chronic kidney disease typically has no cure, it is vital that medical research takes place to find new and more effective treatments for those who have been diagnosed.

Disease 98

More Trending

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending. Click here to see the original post from April 2022.

article thumbnail

Group tour information

Broad Institute

Group tour information By Maria Nemchuk July 29, 2022 Breadcrumb Home Group tour information Welcome Exhibits Plan your visit Book a group tour The Broad Discovery Center offers guided tours to visitors Monday - Wednesday at 11:00 AM, unless otherwise posted. Visitors should gather at the S-shaped sofa in the lobby. Reservations are not required for small groups, but are available to visitors interested in a short, guided experience.

52
article thumbnail

5 ways to lower clinical trial patient recruitment costs

Antidote

The process of getting a new drug to market is an expensive one. Between 2009 and 2018, U.S. biopharmaceutical companies spent about $1 billion per drug according to an analysis published in JAMA , and other studies have found that it can cost up to $2.8 billion to bring a new therapy to market. In 2019 alone, research and development spending totaled $186 billion for the global pharmaceutical industry.

article thumbnail

Which pharmaceutical companies have the most powder dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most powder dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most powder dosed drugs…. The post Which pharmaceutical companies have the most powder dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from April 2022. The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below.

article thumbnail

Preconfigured LIMS Solution for Biobanks and Biorepositories

The Connected Lab

Biobanks play a crucial role in effectively managing and storing critical scientific data: biospecimens. For pharma and biotech companies, diagnostic laboratories, and contract research organizations, specimen integrity is critical to ensure robust and reproducible results. Thermo Scientific™ SampleManager LIMS™ software’s Biorepository Solution is an implementation and validation accelerator which uses industry-standard features, expertise and experience to expedite return on investment and red

article thumbnail

After years with eczema, this young woman found the right treatment — and her people

Antidote

Alexis Smith had eczema as an infant, but had lived a mostly itch-free childhood until hitting puberty at 12. That's when her symptoms came back.

article thumbnail

New patent expiration for Bayer Hlthcare drug BEYAZ

Drug Patent Watch

Annual Drug Patent Expirations for BEYAZ Beyaz is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are three patents…. The post New patent expiration for Bayer Hlthcare drug BEYAZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

DCI’s Top 15 Specialty Pharmacies of 2021—And Three Factors That Will Reshape 2022 (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from May 2022. In Drug Channels Institute’s list of the top 15 pharmacies of 2021 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues.

article thumbnail

Developing Effective Dosing Strategies by Leveraging 3D In Vitro Models

Crown Bioscience

Drug attrition rates remain high, and this has been attributed in part to the poor translatability of current preclinical data. Models that have higher predictivity of patient response are needed.

Drugs 52
article thumbnail

Clean Bench vs Biosafety Cabinet: What’s the Difference?

Advarra

Institutional biosafety committees (IBCs) frequently receive questions about the proper type of hood for use with biological materials and the difference between biosafety cabinets versus clean benches. While both pieces of equipment are hoods with directional airflow, they function differently and are intended for different purposes. This article explores how these tools work and why biosafety cabinets are preferred in research involving cell and gene therapies.

article thumbnail

New patent for Amarin Pharms drug VASCEPA

Drug Patent Watch

Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-eight patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Warped Incentives Update: The Gross-to-Net Bubble Exceeded $200 Billion in 2021 (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. ICYMI, the unimplemented rule to reform rebates in Medicare Part D remains the ultimate budget gimmick. More than $122 billion in "savings" (offsets) from the current drug pricing reconciliation legislation comes from blocking rebate reform—which never even happened.

article thumbnail

Researchers decipher how a gut bacterium influences immunity

Broad Institute

Researchers decipher how a gut bacterium influences immunity By Corie Lok July 26, 2022 Breadcrumb Home News Researchers decipher how a gut bacterium influences immunity Study finds a molecule made by the bacterium that helps moderate immune responses. By Stephanie Dutchen, Harvard Medical School Office of Communications and External Relations July 26, 2022 Credit: Susanna Hamilton, Broad Communications From immunity to metabolism to mental health, it seems like the gut microbiome has been linke

article thumbnail

Regulatory Considerations for Pharmaceutical Product Lifecycle Management

Advarra

As a pharmaceutical product makes its way through the lifecycle, there are often Food and Drug Administration (FDA) guidelines organizations should pay particular attention to. Recent new guidance, “ Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) May 2021 ICH ” now applies to pharmaceutical drug substances and products (both chemic

article thumbnail

New patent for Alk Abello drug OTIPRIO

Drug Patent Watch

Annual Drug Patent Expirations for OTIPRIO Otiprio is a drug marketed by Alk Abello and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Alk Abello drug OTIPRIO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

The Role of High-Content Analysis in 3D Organoid Imaging

Crown Bioscience

High-content analysis (HCA) is a powerful approach for drug discovery and drug validation studies, especially when combined with highly clinically relevant 3D in vitro organoids. Combining these technologies allows you to develop comprehensive cellular profiles of how your compounds are affecting cellular systems and spatial biology. As some researchers may be cautious in employing HCA due to the complexities of the technology and downstream analyses, in this post we provide a brief overview of

article thumbnail

Resources, services, and tools

Broad Institute

Resources, services, and tools By Maria Nemchuk July 26, 2022 Breadcrumb Home Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators. Working with collaborators and contributors around the world, our scientists and engineers are accelerating discovery by: assembling and harmonizing population-scale genomic and health data generating massive, multi-omic biological datasets developing advanced data processing and analysis

article thumbnail

EVENT RECAP 20/15 Visioneers Webinar - Event Recap

The Strateos Blog: Drug Discovery

Strateos had the pleasure of participating with Evariste Technologies in a webinar hosted by 20/15 Visioneers, about cloud lab automation-as-a-service being leveraged to accelerate cycle times for faster drug discovery. 20/15 Visioneers is invested in R&D, IT and informatics solutions to improve efficiencies, collaboration and harmonization driven by FAIR data principles, in silico initiatives and automated cloud labs.

article thumbnail

New patent for Aaa Usa drug LOCAMETZ

Drug Patent Watch

Annual Drug Patent Expirations for LOCAMETZ Locametz is a drug marketed by Aaa Usa Novartis and is included in one NDA. It is available from one supplier. The generic ingredient…. The post New patent for Aaa Usa drug LOCAMETZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Planning a Rare Diseases Clinical Trial? View from United States and Europe

ProRelix Research

Planning a Rare Diseases Clinical Trial? View from United States and Europe The Orphan Drug Act (ODA) defines a rare disease as a disease or condition that affects less than […]. The post Planning a Rare Diseases Clinical Trial? View from United States and Europe appeared first on ProRelix Research.

article thumbnail

Learning resources

Broad Institute

Learning resources By Maria Nemchuk July 26, 2022 Breadcrumb Home Learning resources We are openly sharing our free classroom materials and more for formal and informal STEM educators. Through curriculum guides, explainers, researcher profiles, and more, we aim to support educators as they work to inspire the next generation of biologists, chemists, data scientists, and engineers.

article thumbnail

HB Donor Fragment Selection Themes

Molecular Design

In this post I’ll look at a couple of fragment selection themes with a hydrogen bond donor (HBD) focus. The material has been taken from the recent ‘HBDs in drug design’ preprint (HBD3) which introduced the term ‘hydrogen bond donor-acceptor asymmetry’ and suggested that we need to think differently about HBDs and hydrogen bond acceptors (HBAs) in drug design.

Drugs 52
article thumbnail

New patent for Phathom drug VOQUEZNA TRIPLE PAK

Drug Patent Watch

Annual Drug Patent Expirations for VOQUEZNA+TRIPLE+PAK Voquezna Triple Pak is a drug marketed by Phathom and is included in one NDA. The generic ingredient in VOQUEZNA TRIPLE PAK is amoxicillin;…. The post New patent for Phathom drug VOQUEZNA TRIPLE PAK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Planning a Rare Diseases Clinical Trial? View from United States and Europe

ProRelix Research

Planning a Rare Diseases Clinical Trial? View from United States and Europe The Orphan Drug Act (ODA) defines a rare disease as a disease or condition that affects less than […]. The post Planning a Rare Diseases Clinical Trial? View from United States and Europe appeared first on ProRelix Research.

article thumbnail

Connect with us

Broad Institute

Connect with us By Maria Nemchuk July 26, 2022 Breadcrumb Home News Connect with us We have several ways of sharing our news: Newsletter: Sign up to receive regular email updates on Broad news, research and community. RSS feed: Subscribe to our news and blog RSS feed to receive up-to-the-minute news stories and press releases, as well as other important stories and announcements.

article thumbnail

Too Much “Weight Not Admissibility,” But a Good Result, in D. Minn. Mesh Decision

Drug & Device Law

We confess: we spend much too much time on a prominent social media platform. We post way too many pictures of the Drug and Device Little Rescue Dogs. We follow the progress of our impending addition, a Standard Poodle show puppy, currently in utero. We engage in pointless, angry, political debate. And we look at recipes we will never prepare. One of our favorite recurring memes is the “you had only one job” meme.